Trump Administration Cuts Funding for CREID Infectious Disease Research Network

The Trump administration eliminated funding for the Centers for Research in Emerging Infectious Diseases (CREID) network in 2025, ending a research initiative that had been positioned as a key component of pandemic preparedness infrastructure. The National Institutes of Health confirmed that CREID work would not continue under the new funding priorities.

The CREID network comprised multiple research centers strategically positioned in regions around the globe where emerging and re-emerging infectious disease outbreaks are most likely to occur. The network had been established through 11 grants totaling approximately $17 million in first-year funding from the National Institute of Allergy and Infectious Diseases (NIAID).

Network Structure and Research Focus

CREID investigators developed reagents and diagnostic assays to improve detection of emerging pathogens, while conducting parallel research into human immune responses to new or emerging infectious agents. The network operated under coordination from RTI International in Research Triangle Park, North Carolina, working in collaboration with Duke University, Durham, North Carolina, which received funding to establish a CREID Coordinating Center.

Among the centers comprising the network was the West African Center for Emerging Infectious Diseases (WAC-EID), led by Scott Weaver, a professor at the University of Texas Medical Branch who served as the center's principal investigator.

The research approach emphasized cross-disciplinary collaboration, drawing on expertise spanning biological, physical and social sciences, along with engineering capabilities. This methodology aligned with broader National Science Foundation support for emerging infectious disease research through similar interdisciplinary frameworks.

Relationship to Existing CDC Infrastructure

The termination of CREID funding affects research infrastructure that operated alongside, but separately from, the CDC's Emerging Infections Program (EIP). The EIP maintains a network of 12 US sites focused on translating infectious disease research into informed policy and public health practice, and has operated for nearly three decades producing surveillance and research on emerging infectious diseases.

While both programs addressed emerging infectious disease threats, CREID's mandate extended to international research locations and emphasized rapid-response diagnostic development, distinguishing it from the EIP's domestic surveillance and policy translation mission.

Historical Context and Pattern Recognition

Looking at the broader arc of federal research funding, this represents a familiar pattern where new administrations redirect scientific priorities based on policy preferences rather than technical merit assessments. We witnessed similar dynamics during the early 2000s with stem cell research restrictions, and again in the late 2010s with climate science program modifications.

What makes the CREID termination particularly notable is the timing relationship to recent pandemic experience. The network's diagnostic assay development and pathogen detection capabilities were explicitly designed to address gaps revealed during COVID-19 response efforts.

The decision also affects international research partnerships that had been developed over multiple funding cycles. These collaborations typically require years to establish effective working relationships with institutions in outbreak-prone regions, making restart costs higher than simple budget line restoration.

Technical Implications for Preparedness Infrastructure

The elimination of CREID funding removes dedicated capacity for rapid diagnostic development in response to novel pathogen emergence. This capability gap becomes particularly significant for pathogens that emerge in regions where established diagnostic infrastructure may be limited.

CREID's emphasis on human immune response research also addressed critical knowledge gaps in understanding how different populations respond to novel infectious agents. This research foundation supports both therapeutic development and public health response strategy formulation.

The network's reagent development work provided standardized materials for research institutions worldwide, enabling more consistent and comparable research results across different laboratories and geographic regions.

Broader Research Ecosystem Impact

Beyond the immediate research capacity loss, the funding termination affects the career pipeline for infectious disease researchers. The CREID network provided funding for graduate students, postdoctoral researchers, and early-career faculty whose work focused on emerging pathogen research.

International collaborations developed through CREID partnerships often serve as foundations for future research relationships, extending beyond the specific funded projects. These networks typically persist informally even after formal funding ends, but lose the coordination and resource-sharing capabilities that federal funding enables.

The decision occurs within a broader context of federal research funding adjustments, as the administration prioritizes different scientific domains. However, infectious disease research funding cuts contrast with increased allocations in areas such as artificial intelligence and semiconductor research, where national security implications receive different policy weighting.

Worth flagging: The timing of this funding termination, occurring during a period when infectious disease threats remain elevated globally, raises questions about the balance between short-term budget considerations and long-term preparedness infrastructure maintenance. The specialized expertise and international partnerships that CREID had developed cannot be quickly reconstituted when the next emerging pathogen appears.

The research community now faces the challenge of maintaining critical capabilities through alternative funding mechanisms, while hoping that private foundation support or state-level initiatives might partially offset the federal capacity reduction.